Suppr超能文献

小儿肾移植术后快速停用类固醇:单中心经验

Rapid steroid discontinuation for pediatric renal transplantation: a single center experience.

作者信息

Lau Keith K, Haddad Maha N, Berg Gerre M, Perez Richard V, Butani Lavjay

机构信息

Department of Pediatrics, University of California-Davis, 2526 Stockton Boulevard, Sacramento, CA 95817, USA.

出版信息

Pediatr Transplant. 2007 Aug;11(5):504-10. doi: 10.1111/j.1399-3046.2007.00713.x.

Abstract

To determine the outcomes of pediatric renal transplant recipients who received immunosuppression consisting of early withdrawal of corticosteroids at a single Northern California center. Protocols using minimal steroid exposure have been recently reported in adult transplant recipients with successful results. We examined the outcomes of pediatric renal transplant recipients who were managed at our center using a protocol with very early discontinuation of steroids after renal transplantation. We retrospectively studied the medical records of all renal transplant recipients followed at the Children's Hospital at the University of California, Davis Medical Center from 01/2004 to 12/2005. All patients were less than 18 yr of age at the time of transplantation. The immunosuppressive protocol included three tapering daily doses of methylprednisolone, together with five doses of thymoglobulin followed by maintenance therapy with tacrolimus and MMF. Eight patients with equal numbers of males and females were transplanted during this time period. There were equal numbers of Caucasians, African-Americans, Hispanics, and Asians. A total of 37.5% (3/8) of the subjects received preemptive transplantation, 25% (2/8) received peritoneal, and 37.5% (3/8) received hemodialysis before transplantation. The median (range) age at transplantation was 12.3 (3.1-16.0) year with a follow-up of 1.7 (0.9-2.8) year. At one yr post-transplantation, 57% (4/7) of patients still required anti-hypertensives. Three children required erythropoietin supplementation after transplantation. The mean delta height standard deviation score at 12 months was 0.20 +/- 0.56. There were no episodes of clinical acute rejection. One patient switched from tacrolimus to sirolimus due to biopsy-proven CAN. No patient became diabetic or required hypoglycemic agents. Surveillance biopsies showed no subclinical acute rejection in any patient. Steroid-free immunosuppression is safe in children after renal transplantation. Larger number of patients and longer follow-up are required to further confirm the effectiveness and safety of immunosuppression with rapid steroid discontinuation.

摘要

为了确定在北加利福尼亚州一家中心接受免疫抑制治疗(包括早期停用皮质类固醇)的小儿肾移植受者的治疗结果。最近有报道称,在成人移植受者中使用最小化类固醇暴露的方案取得了成功。我们研究了在我们中心接受肾移植后采用极早期停用类固醇方案治疗的小儿肾移植受者的治疗结果。我们回顾性研究了2004年1月至2005年12月在加利福尼亚大学戴维斯分校医学中心儿童医院接受随访的所有肾移植受者的病历。所有患者在移植时年龄均小于18岁。免疫抑制方案包括每日三次逐渐减量的甲泼尼龙剂量,以及五剂胸腺球蛋白,随后用他克莫司和霉酚酸酯进行维持治疗。在此期间有8名患者接受了移植,男女数量相等。白种人、非裔美国人、西班牙裔和亚洲人的数量相等。共有37.5%(3/8)的受试者接受了抢先移植,25%(2/8)接受了腹膜透析,37.5%(3/8)在移植前接受了血液透析。移植时的中位(范围)年龄为12.3(3.1 - 16.0)岁,随访时间为1.7(0.9 - 2.8)年。移植后1年,57%(4/7)的患者仍需要抗高血压药物。三名儿童在移植后需要补充促红细胞生成素。12个月时的平均身高标准差差值评分是0.20±0.56。没有临床急性排斥反应事件。一名患者因活检证实的慢性移植物肾病从他克莫司转换为西罗莫司。没有患者患糖尿病或需要使用降糖药。监测活检显示所有患者均无亚临床急性排斥反应。肾移植后儿童采用无类固醇免疫抑制是安全的。需要更多患者和更长时间的随访来进一步证实快速停用类固醇免疫抑制的有效性和安全性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验